2 news items
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
OCUP
VTRS
10 May 24
Protocol Assessment (SPA) to formalize the protocol and statistical analysis plan for future Phase 2/3 registrational trials of APX3330 in diabetic
Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline
VTRS
27 Mar 24
) global Phase 3 multi-center trial. This cardiovascular outcomes-based trial has received Special Protocol Assessment (SPA) agreement from the U.S. Food
- Prev
- 1
- Next